Past, Present and Future: SGLT2 inhibitors for CV Outcomes

Published: 17 August 2020

  • Views:

    Views Icon 113
  • Likes:

    Heart Icon 0

Overview

Full programme

  • Views:

    Views Icon 113
  • Likes:

    Heart Icon 0

Overview

This roundtable event includes four leading heart failure specialists discussing recent data related to SGLT2 inhibitors in reducing CV risk, HF hospitalisations and mortality and morbidity in HFrEF irrespective of T2DM. The panel also look at ongoing studies including those for HFpEF and CKD outcomes.

 

This video series was funded by an unrestricted educational grant from Boehringer Ingelheim.

Educational Objectives

  • Understand the History of SGLT2 Inhibitors and the Published Data from SGLT-2 Inhibitor Cardiovascular Outcome Trials (CVOT).
  • Link These Outcomes Data to the Latest Guideline Updates in Diabetes.
  • Understand the Importance of the Ongoing CREDENCE, EMPA and DAPA Clinical Trials.
  • Evaluate Emerging Data of the Treatment of HF With SGLT2 Inhibitors in Patients With or Without T2DM.
  • Apply This Clinical Understanding to the Management of Heart Failure Patients in the Real World.
  • Identify Important Future Developments to Be Aware of to Allow Continual Optimisation of Heart Failure Management and the Potential for Future Guideline Updates in Heart Failure
  • Assess the Interrelationships Linking Diabetes, HF and CVD

Series overview

Part 1

How Did We Get Here?

Test description

1 session

Part 2

Where Are We Now?

1 session

Part 3

What Is the Future?

1 session

Faculty biographies